Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Rating of “Hold” from Analysts

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Rating) have been assigned an average rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $7.92.

Several brokerages have recently commented on ASMB. StockNews.com began coverage on shares of Assembly Biosciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial reduced their target price on shares of Assembly Biosciences from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, April 1st. Zacks Investment Research cut Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 4th. Finally, Mizuho began coverage on Assembly Biosciences in a report on Tuesday, March 22nd. They issued a “buy” rating and a $14.00 price target for the company.

ASMB opened at $2.02 on Monday. The business has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.20. Assembly Biosciences has a twelve month low of $1.40 and a twelve month high of $4.69. The firm has a market cap of $97.20 million, a P/E ratio of -0.67 and a beta of 0.86.

Assembly Biosciences (NASDAQ:ASMB – Get Rating) last announced its quarterly earnings data on Thursday, March 10th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.09. On average, research analysts expect that Assembly Biosciences will post -2 EPS for the current year.

Several large investors have recently modified their holdings of the stock. Deep Track Capital LP bought a new position in shares of Assembly Biosciences in the 4th quarter valued at about $6,990,000. BlackRock Inc. boosted its holdings in shares of Assembly Biosciences by 3.0% during the 3rd quarter. BlackRock Inc. now owns 1,969,977 shares of the biopharmaceutical company’s stock worth $6,855,000 after buying an additional 57,883 shares during the period. Candriam Luxembourg S.C.A. boosted its holdings in shares of Assembly Biosciences by 25.1% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,838,221 shares of the biopharmaceutical company’s stock worth $4,283,000 after buying an additional 369,375 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 13.9% during the 4th quarter. Acadian Asset Management LLC now owns 1,608,760 shares of the biopharmaceutical company’s stock worth $3,746,000 after buying an additional 196,033 shares during the period. Finally, Hudson Bay Capital Management LP boosted its holdings in shares of Assembly Biosciences by 13.3% during the 3rd quarter. Hudson Bay Capital Management LP now owns 850,000 shares of the biopharmaceutical company’s stock worth $2,958,000 after buying an additional 100,000 shares during the period. Institutional investors and hedge funds own 52.45% of the company’s stock.

Assembly Biosciences Company Profile (Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

Recommended Stories